Prochlorperazine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal drug-induced neurological emergency. The case report Prochlorperazine-induced neuroleptic malignant syndrome is clinically important because it documents a classic NMS phenotype after prochlorperazine exposure while several commonly expected laboratory abnormalities were absent or only mildly expressed. For emergency and neurology researchers, the report illustrates why diagnosis must remain clinically grounded rather than dependent on a single biomarker.

Study Background and Research Question

NMS is most often associated with dopamine-receptor-blocking antipsychotics, although other dopamine-antagonist drugs can also be implicated. The syndrome typically combines hyperthermia, altered consciousness, autonomic dysregulation, and generalized muscle rigidity. Its clinical overlap with serotonin syndrome, central nervous system infection, malignant hyperthermia, malignant catatonia, seizures, and other toxic-metabolic disorders makes early recognition challenging.

The reference study addresses a focused question: can prochlorperazine, prescribed for nausea associated with peripheral vertigo, precipitate NMS in an older patient receiving a standard regimen? The patient was a 76-year-old man with hypertension, type 2 diabetes, and chronic atrial fibrillation. He had received prochlorperazine at 5 mg twice daily for two weeks before developing fever and acute mental-status changes. The case therefore examines both drug attribution and the diagnostic consequences of an atypical laboratory profile.

The authors also ask how clinicians should distinguish NMS from competing neurological emergencies when the presentation is suggestive but not accompanied by marked leukocytosis, electrolyte disturbance, or a very high creatine phosphokinase concentration. This is a practical diagnostic problem rather than a question of treatment efficacy in a controlled population.

Key Innovation from the Reference Study

The main innovation is the detailed description of prochlorperazine-associated NMS in a geriatric patient at a conventional dose. Prochlorperazine is widely used as an antiemetic and for vertigo-related symptoms, so its potential contribution to NMS may be overlooked when clinicians associate the syndrome primarily with psychiatric antipsychotics. The report broadens the medication-history question from antipsychotic use to any recent exposure to a dopamine-blocking agent.

The second important contribution is the contrast between the strong clinical syndrome and the limited biochemical signal. The patient had fever above 38 °C, autonomic instability, altered consciousness, tremor, and generalized leadpipe rigidity, yet the initial creatine phosphokinase level was only 256 U/L and later peaked at 454 U/L. The report also describes a normal white blood cell count, normal electrolytes, normal blood ammonia, and normal blood-gas analysis. These findings show that NMS cannot be excluded solely because creatine phosphokinase is not dramatically elevated.

Finally, the case provides a clinically useful treatment narrative. Symptoms improved progressively during treatment with a benzodiazepine and amantadine, with recovery of consciousness and resolution of rigidity. Because this is a single case, the observation is hypothesis-generating rather than proof that either drug is superior; its value lies in showing a workable response in a patient whose diagnosis was made primarily from clinical evidence.

Methods and Experimental Design Insights

This was a structured case report rather than an interventional or observational cohort study. The methodology integrated exposure history, symptom chronology, neurological examination, laboratory testing, neuroimaging, cerebrospinal-fluid analysis, electroencephalography, treatment, and follow-up. That multimodal approach is appropriate for NMS because no single test establishes the diagnosis.

The medication history was particularly informative. The patient had taken his established long-term medications for chronic diseases and had no newly introduced medication other than prochlorperazine during the preceding two weeks. The authors then assessed the temporal relationship between exposure and symptoms, examined for the characteristic motor and autonomic findings, and evaluated alternative explanations.

Physical examination documented drowsiness, lethargy, reduced motor activity, tremor, generalized rigidity, and reduced deep-tendon reflexes. Neurological impairment was quantified with a Glasgow Coma Scale score of 12 at admission. Brain computed tomography did not show acute intracranial pathology. Lumbar puncture found mildly increased cerebrospinal-fluid protein at 66 mg/dL with otherwise normal findings, while electroencephalography showed no epileptiform discharges. Together, these investigations reduced the likelihood of structural brain disease, overt central nervous system infection, or an ongoing epileptic process, although they did not independently diagnose NMS.

Protocol Parameters

• Exposure review: Examine all recent dopamine-blocking and serotonergic medications, including indication, dose, duration, and timing relative to symptom onset. In this case, prochlorperazine had been prescribed at 5 mg twice daily for two weeks, according to the reference report.
• Initial syndrome assessment: Record temperature, heart rate, respiratory rate, blood-pressure variability, consciousness, rigidity, tremor, and reflexes. The reported patient had fever above 38 °C, a heart rate over 100 beats per minute, a respiratory rate above 30 breaths per minute, labile blood pressure, and a GCS score of 12.
• Laboratory interpretation: Use serial creatine phosphokinase, blood count, electrolytes, ammonia, and blood-gas testing as supportive data rather than exclusion criteria. The case showed a creatine phosphokinase value of 256 U/L initially and 454 U/L at its later peak, with otherwise limited laboratory abnormalities.
• Evaluation of mimics: Select imaging, cerebrospinal-fluid studies, and electroencephalography according to the neurological presentation. In the report, CT was unremarkable, cerebrospinal-fluid protein was 66 mg/dL with otherwise normal findings, and EEG had no epileptiform discharges.
• Case-specific pharmacotherapy: The reported regimen was intravenous lorazepam at 1 mg every six hours and oral amantadine at 100 mg every 12 hours. These are treatment details from one case, not a universal dosing protocol; clinical management should follow local emergency and critical-care guidance.

Core Findings and Why They Matter

The patient presented with the four major clinical domains of NMS: hyperthermia, mental-status alteration, autonomic instability, and severe rigidity. This clustering was more diagnostically informative than any individual laboratory result. In particular, generalized leadpipe rigidity with hyporeflexia favored NMS over serotonin syndrome, which more commonly produces hyperreflexia, clonus, and gastrointestinal hyperactivity. The absence of serotonin-related medications further weakened the serotonin-syndrome hypothesis, as discussed in the published case analysis.

The normal white blood cell count and modest creatine phosphokinase response are meaningful because they demonstrate phenotypic variability. Creatine phosphokinase may rise with sustained muscle injury, but its magnitude can depend on disease duration, muscle activity, hydration, timing of measurement, and individual factors. A modest result should therefore prompt continued clinical reasoning rather than premature dismissal of NMS.

The therapeutic course was favorable. After lorazepam and amantadine were initiated, fever resolved, consciousness improved to a full GCS score of 15, and generalized rigidity disappeared. Lorazepam was tapered, while amantadine was continued after discharge and later discontinued when follow-up examinations showed no recurrent altered mental status or rigidity. The sequence supports the importance of early recognition and continued neurological observation, but it cannot separate the effects of medication, supportive care, natural recovery, and removal of the suspected trigger.

For research design, the case suggests that future pharmacovigilance studies should capture indication-specific use of prochlorperazine, patient age, comorbidities, duration of exposure, neurological findings, and serial rather than single creatine phosphokinase values. Such variables could help identify whether older adults or medically complex patients have distinct presentations.

Comparison with Existing Internal Articles

The available internal resources address a different evidence domain. One summary discusses a natural flavonoid antioxidant in relation to mitochondrial energy metabolism, while another describes inhibition of adenosine 5′-monophosphate deaminase 2 in podocytes and fructose-associated cellular injury. These resources can be useful for researchers studying oxidative stress or metabolic injury, but they are not direct comparators for an acute dopamine-blockade syndrome.

The contrast is nevertheless informative. The reference case is a human emergency-medicine report centered on bedside diagnosis and treatment response. By comparison, the podocyte mitochondrial-function summary concerns a mechanistic disease model, and the flavonoid antioxidant overview describes biochemical and translational research applications. Their endpoints, biological systems, and causal claims differ substantially from those in the NMS report.

Why this cross-domain matters, maturity, and limitations

Cross-domain comparison matters because researchers may encounter both acute neurotoxicity studies and antioxidant or mitochondrial assays in broader drug-safety workflows. However, the evidence remains immature for any inference that a compound studied in metabolic or oxidative-stress models would prevent or treat prochlorperazine-induced NMS. The internal resources do not provide clinical evidence for NMS, and the reference report does not test antioxidant, mitochondrial, or flavonoid interventions. The appropriate connection is methodological: both domains require careful exposure characterization and mechanistic restraint, not therapeutic extrapolation.

Limitations and Transferability

The most important limitation is the single-patient design. A case report cannot estimate incidence, identify independent risk factors, compare prochlorperazine with other dopamine antagonists, or establish the frequency of laboratory-negative presentations. The patient’s advanced age and multiple chronic conditions may have influenced susceptibility, symptom expression, pharmacokinetics, or recovery, limiting transferability to younger or less medically complex populations.

Causality is also necessarily probabilistic. The temporal association with prochlorperazine and the absence of another newly introduced medication support the authors’ interpretation, but there was no controlled rechallenge, drug-concentration analysis, or comparative treatment arm. In addition, improvement followed combined management with lorazepam, amantadine, monitoring, and supportive hospital care. The report therefore supports recognition of a possible adverse drug reaction, not a definitive estimate of the relative efficacy of the administered agents.

Diagnostic uncertainty cannot be eliminated by the reported negative tests. Normal CT, largely unremarkable cerebrospinal fluid, and a non-epileptiform EEG help evaluate alternatives but do not rule out every infectious, inflammatory, metabolic, or toxic process. Similarly, the modest creatine phosphokinase elevation should be interpreted in relation to symptom timing and serial examination. These limitations reinforce the central practical lesson: NMS remains a clinical diagnosis supported by investigations, not a laboratory diagnosis with a reliable single cutoff.

Despite these constraints, the case is transferable as a reasoning framework. In patients with fever, mental-status change, autonomic instability, and rigidity, clinicians should actively review recent medications, recognize that standard dosing does not eliminate risk, assess mimics, and monitor neurological and laboratory trajectories. Researchers designing future studies should preserve this multidimensional data structure.

Research Support Resources

For related oxidative-stress, mitochondrial, or biochemical assay workflows, researchers can use Morin (SKU C5297), chemically identified as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. The product information describes research applications of this natural flavonoid as a cardioprotective and neuroprotective agent and as an anti-inflammatory flavonoid for diabetes research; separate assays examine its fluorescent aluminum ion probe properties and inhibition of adenosine 5′-monophosphate deaminase. These applications are mechanistically distinct from NMS and should not be interpreted as a treatment recommendation for the syndrome.